Elizabeth Keating O'Donnell, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 27 | 2023 | 5181 | 2.680 |
Why?
|
Hepatitis, Viral, Human | 1 | 2024 | 138 | 0.900 |
Why?
|
Paraproteinemias | 1 | 2024 | 246 | 0.780 |
Why?
|
Testicular Neoplasms | 7 | 2019 | 806 | 0.540 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 5 | 2019 | 501 | 0.490 |
Why?
|
Bone Density Conservation Agents | 2 | 2018 | 772 | 0.480 |
Why?
|
Diphosphonates | 1 | 2018 | 623 | 0.470 |
Why?
|
Bone Diseases | 1 | 2017 | 416 | 0.450 |
Why?
|
Immunotherapy, Adoptive | 4 | 2022 | 1271 | 0.350 |
Why?
|
Whole Body Imaging | 2 | 2021 | 280 | 0.310 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 11525 | 0.310 |
Why?
|
Bone Marrow | 5 | 2021 | 2948 | 0.290 |
Why?
|
Fasting | 2 | 2022 | 1592 | 0.260 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 2 | 2018 | 177 | 0.260 |
Why?
|
Indoles | 1 | 2013 | 1839 | 0.250 |
Why?
|
Fatigue | 2 | 2022 | 1531 | 0.250 |
Why?
|
B-Cell Maturation Antigen | 2 | 2022 | 140 | 0.230 |
Why?
|
Sulfonamides | 1 | 2013 | 1940 | 0.230 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2013 | 2043 | 0.230 |
Why?
|
Seminoma | 2 | 2015 | 139 | 0.220 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2021 | 5445 | 0.220 |
Why?
|
Antibodies, Bispecific | 1 | 2023 | 164 | 0.200 |
Why?
|
Waldenstrom Macroglobulinemia | 2 | 2021 | 1052 | 0.190 |
Why?
|
Mutation | 4 | 2018 | 29786 | 0.190 |
Why?
|
Quality of Life | 4 | 2022 | 12802 | 0.190 |
Why?
|
Plasma Cells | 1 | 2024 | 591 | 0.180 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2022 | 648 | 0.180 |
Why?
|
Neurotoxicity Syndromes | 1 | 2023 | 290 | 0.170 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2020 | 113 | 0.170 |
Why?
|
Adenine | 2 | 2021 | 936 | 0.160 |
Why?
|
Dexamethasone | 3 | 2023 | 1951 | 0.150 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2023 | 9240 | 0.150 |
Why?
|
Humans | 43 | 2024 | 744366 | 0.150 |
Why?
|
Boron Compounds | 1 | 2018 | 178 | 0.150 |
Why?
|
Aged | 18 | 2022 | 163288 | 0.140 |
Why?
|
Prognosis | 6 | 2022 | 29060 | 0.140 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2022 | 2016 | 0.140 |
Why?
|
Transplantation, Autologous | 1 | 2021 | 2124 | 0.140 |
Why?
|
Administration, Cutaneous | 1 | 2018 | 711 | 0.140 |
Why?
|
Antineoplastic Agents | 4 | 2018 | 13693 | 0.130 |
Why?
|
Piperidines | 2 | 2021 | 1602 | 0.130 |
Why?
|
Carcinoma, Embryonal | 1 | 2015 | 38 | 0.130 |
Why?
|
Decorin | 1 | 2015 | 40 | 0.130 |
Why?
|
Osteocytes | 1 | 2017 | 197 | 0.130 |
Why?
|
Glycine | 1 | 2018 | 671 | 0.130 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2014 | 15520 | 0.130 |
Why?
|
Osteolysis | 1 | 2017 | 270 | 0.130 |
Why?
|
Pyrimidines | 2 | 2018 | 2943 | 0.120 |
Why?
|
Breast Neoplasms | 1 | 2022 | 20824 | 0.120 |
Why?
|
Abdominal Fat | 1 | 2016 | 223 | 0.120 |
Why?
|
Vision Disorders | 1 | 2021 | 1058 | 0.110 |
Why?
|
Lymphoma | 1 | 2022 | 1877 | 0.110 |
Why?
|
Lymph Nodes | 2 | 2015 | 3476 | 0.110 |
Why?
|
Osteoclasts | 1 | 2017 | 729 | 0.110 |
Why?
|
Cross-Sectional Studies | 3 | 2022 | 25039 | 0.110 |
Why?
|
Pilot Projects | 2 | 2022 | 8319 | 0.100 |
Why?
|
Hydroxamic Acids | 1 | 2015 | 494 | 0.100 |
Why?
|
Adjuvants, Immunologic | 1 | 2017 | 1000 | 0.100 |
Why?
|
Osteoblasts | 1 | 2017 | 1166 | 0.100 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2014 | 340 | 0.100 |
Why?
|
Tomography, X-Ray Computed | 3 | 2021 | 20130 | 0.100 |
Why?
|
Middle Aged | 16 | 2022 | 213390 | 0.090 |
Why?
|
Caregivers | 1 | 2022 | 2095 | 0.090 |
Why?
|
Administration, Oral | 1 | 2018 | 3914 | 0.090 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4933 | 0.090 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 1378 | 0.090 |
Why?
|
Castration | 1 | 2009 | 159 | 0.090 |
Why?
|
Oligopeptides | 1 | 2015 | 1189 | 0.090 |
Why?
|
Prospective Studies | 4 | 2022 | 53290 | 0.090 |
Why?
|
Adipose Tissue | 1 | 2021 | 3280 | 0.080 |
Why?
|
Male | 22 | 2021 | 350115 | 0.080 |
Why?
|
Positron-Emission Tomography | 2 | 2022 | 6234 | 0.080 |
Why?
|
Pyrazoles | 1 | 2018 | 1972 | 0.080 |
Why?
|
Disease-Free Survival | 1 | 2018 | 6896 | 0.080 |
Why?
|
Female | 15 | 2022 | 380193 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 6539 | 0.070 |
Why?
|
Neoplasms, Second Primary | 1 | 2015 | 1062 | 0.070 |
Why?
|
Acute Kidney Injury | 1 | 2020 | 1968 | 0.070 |
Why?
|
Adult | 10 | 2022 | 214052 | 0.070 |
Why?
|
Treatment Outcome | 7 | 2018 | 63107 | 0.070 |
Why?
|
Aged, 80 and over | 5 | 2021 | 57776 | 0.070 |
Why?
|
Stress, Psychological | 1 | 2022 | 4245 | 0.070 |
Why?
|
Mesenchymal Stem Cells | 1 | 2017 | 1632 | 0.070 |
Why?
|
Carboplatin | 1 | 2009 | 801 | 0.070 |
Why?
|
Taxoids | 1 | 2009 | 666 | 0.070 |
Why?
|
Molecular Targeted Therapy | 1 | 2017 | 2725 | 0.070 |
Why?
|
Liver | 1 | 2021 | 7475 | 0.060 |
Why?
|
Cell Line, Tumor | 3 | 2015 | 16690 | 0.060 |
Why?
|
Genome, Human | 1 | 2016 | 4420 | 0.060 |
Why?
|
Exercise | 1 | 2020 | 5615 | 0.060 |
Why?
|
Retrospective Studies | 6 | 2022 | 77460 | 0.060 |
Why?
|
Depression | 1 | 2022 | 7759 | 0.050 |
Why?
|
Neoplasm Metastasis | 3 | 2019 | 4851 | 0.050 |
Why?
|
Tumor Microenvironment | 1 | 2015 | 3590 | 0.050 |
Why?
|
Diagnostic Imaging | 1 | 2017 | 3508 | 0.050 |
Why?
|
Follow-Up Studies | 6 | 2022 | 39052 | 0.050 |
Why?
|
Apoptosis | 2 | 2016 | 9724 | 0.050 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2016 | 5172 | 0.050 |
Why?
|
Young Adult | 5 | 2019 | 56429 | 0.050 |
Why?
|
Treatment Failure | 2 | 2022 | 2618 | 0.050 |
Why?
|
Methionine | 1 | 2022 | 590 | 0.050 |
Why?
|
Consensus | 2 | 2022 | 2960 | 0.040 |
Why?
|
Liver Function Tests | 1 | 2021 | 528 | 0.040 |
Why?
|
Habits | 1 | 2020 | 139 | 0.040 |
Why?
|
Water-Electrolyte Balance | 1 | 2020 | 346 | 0.040 |
Why?
|
Neoplasm Staging | 3 | 2019 | 11031 | 0.040 |
Why?
|
Biopsy | 2 | 2021 | 6755 | 0.040 |
Why?
|
Neutropenia | 1 | 2022 | 895 | 0.040 |
Why?
|
Adolescent | 4 | 2018 | 85779 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 2 | 2021 | 35425 | 0.040 |
Why?
|
Neoplasm, Residual | 1 | 2021 | 973 | 0.040 |
Why?
|
Obesity | 1 | 2019 | 12746 | 0.040 |
Why?
|
Lymphatic Metastasis | 2 | 2014 | 2924 | 0.030 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2016 | 223 | 0.030 |
Why?
|
Lymphocytes | 1 | 2023 | 2617 | 0.030 |
Why?
|
United States | 2 | 2021 | 69872 | 0.030 |
Why?
|
Plasmacytoma | 1 | 2015 | 183 | 0.030 |
Why?
|
Loss of Heterozygosity | 1 | 2016 | 684 | 0.030 |
Why?
|
Survival Rate | 2 | 2021 | 12788 | 0.030 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2018 | 571 | 0.030 |
Why?
|
Recurrence | 2 | 2017 | 8340 | 0.030 |
Why?
|
Teratoma | 1 | 2016 | 395 | 0.030 |
Why?
|
Phagosomes | 1 | 2015 | 193 | 0.030 |
Why?
|
Needs Assessment | 1 | 2020 | 1147 | 0.030 |
Why?
|
Risk Assessment | 1 | 2015 | 23336 | 0.030 |
Why?
|
Receptors, CXCR4 | 1 | 2018 | 727 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2022 | 2645 | 0.030 |
Why?
|
Combined Modality Therapy | 2 | 2015 | 8642 | 0.030 |
Why?
|
Health Services Needs and Demand | 1 | 2020 | 1410 | 0.030 |
Why?
|
Neoplasms | 1 | 2020 | 21696 | 0.020 |
Why?
|
Boronic Acids | 1 | 2015 | 965 | 0.020 |
Why?
|
Drug Synergism | 1 | 2015 | 1794 | 0.020 |
Why?
|
Animals | 3 | 2017 | 168768 | 0.020 |
Why?
|
Thalidomide | 1 | 2015 | 890 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2018 | 1928 | 0.020 |
Why?
|
Salvage Therapy | 1 | 2016 | 1275 | 0.020 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2015 | 789 | 0.020 |
Why?
|
Remission Induction | 1 | 2015 | 2385 | 0.020 |
Why?
|
Phylogeny | 1 | 2016 | 2804 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1692 | 0.020 |
Why?
|
Interdisciplinary Communication | 1 | 2015 | 950 | 0.020 |
Why?
|
Pyrazines | 1 | 2015 | 1230 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3595 | 0.020 |
Why?
|
Evolution, Molecular | 1 | 2016 | 1939 | 0.020 |
Why?
|
Tumor Burden | 1 | 2013 | 1915 | 0.020 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2014 | 1184 | 0.020 |
Why?
|
Lymph Node Excision | 1 | 2013 | 1262 | 0.020 |
Why?
|
Autophagy | 1 | 2015 | 1297 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2015 | 3616 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2018 | 4805 | 0.020 |
Why?
|
Adiposity | 1 | 2016 | 1806 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2009 | 11126 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 2949 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12961 | 0.020 |
Why?
|
Palliative Care | 1 | 2020 | 3493 | 0.020 |
Why?
|
Cell Survival | 1 | 2015 | 5882 | 0.020 |
Why?
|
Disease Management | 1 | 2015 | 2460 | 0.020 |
Why?
|
Population Surveillance | 1 | 2015 | 2616 | 0.020 |
Why?
|
Survival Analysis | 1 | 2017 | 10252 | 0.010 |
Why?
|
Logistic Models | 1 | 2019 | 13409 | 0.010 |
Why?
|
Mitochondria | 1 | 2016 | 3514 | 0.010 |
Why?
|
Risk | 1 | 2015 | 9688 | 0.010 |
Why?
|
Body Mass Index | 1 | 2019 | 12721 | 0.010 |
Why?
|
Genomics | 1 | 2016 | 5717 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2018 | 21748 | 0.010 |
Why?
|
Disease Progression | 1 | 2016 | 13286 | 0.010 |
Why?
|
Age Factors | 1 | 2016 | 18373 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2014 | 14723 | 0.010 |
Why?
|
Mice | 2 | 2015 | 81201 | 0.010 |
Why?
|
Risk Factors | 2 | 2015 | 72296 | 0.010 |
Why?
|
Incidence | 1 | 2015 | 20952 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2014 | 19905 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2015 | 18034 | 0.010 |
Why?
|
Cohort Studies | 1 | 2017 | 40559 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2009 | 7914 | 0.010 |
Why?
|